Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jcrc.2020.06.019 http://scihub22266oqcxt.onion/10.1016/j.jcrc.2020.06.019 32683212!7351664!32683212     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Crit+Care 2020 ; 59 (ä): 176-190 Nephropedia Template TP {{tp|p=32683212|t=2020. Update I A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 |pdf=|usr=}}{{32683212}} gab.com Text Update I A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 JO: J Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=32683212 #FOAvip PURPOSE: To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans. MATERIALS AND METHODS: MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19. RESULTS: Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two 'some concerns' and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low. CONCLUSIONS: Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed. Twit Text FOAVip Update I A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 ????J Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=32683212 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32683212 #FOAvip English Wikipedia <ref>{{Cite pmid|32683212}}</ref> Update I A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 #MMPMID32683212 Cortegiani A; Ippolito M; Ingoglia G; Iozzo P; Giarratano A; Einav S J Crit Care 2020[Oct]; 59 (ä): 176-190 PMID32683212show ga PURPOSE: To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans. MATERIALS AND METHODS: MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19. RESULTS: Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two 'some concerns' and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low. CONCLUSIONS: Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed. |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chloroquine/*therapeutic use[MESH] |Coronavirus Infections/*drug therapy/prevention & control[MESH] |Humans[MESH] |Hydroxychloroquine/*therapeutic use[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/*drug therapy/prevention & control[MESH] |Post-Exposure Prophylaxis[MESH] |Prospective Studies[MESH] |Retrospective Studies[MESH]Update I A systematic review on the efficacy and safety of chloroqui(epmc).pdf DeepDyve Pubget Overpricing